Calliditas Therapeutics AB (publ)
Calliditas Therapeutics AB (publ) (CALT) Stock Forecast & Price Predictions
Get the latest Calliditas Therapeutics AB (publ) (CALT) stock forecast across short-term and long-term horizons. Meyka AI generates price predictions using advanced models trained on historical data. These forecasts are not investment advice but directional insights to help investors and traders plan strategies.
Model Information
The Forecast Prediction Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerMonthly Forecast
Quarterly Forecast
Yearly Forecast
3 Years Forecast
5 Years Forecast
7 Years Forecast
Calliditas Therapeutics AB (publ) Stock Forecast Summary
Calliditas Therapeutics AB (publ) (CALT) stock is currently priced at $40.00. Based on Meyka AI predictions, the short-term outlook is bearish, with momentum pointing higher. The 1-month projection suggests a move toward N/A.
In the long term, CALT shows a bullish trend. The 2027 forecast points to $50.22 (25.55% change), while the 2031 forecast suggests $80.89 (102.23% change). Looking 7 years ahead, projections estimate the stock could trade near $83.17, a 107.91% change from today’s price.
Neutral
Bearish
Bullish
This mix indicates that Calliditas Therapeutics AB (publ) stock is expected to rise steadily over the coming years.
Investment Calculator
Estimate your potential returns on CALT using our advanced Investment Calculator with AI-driven price forecasts. Enter your investment amount and select a target date to view expected results, including estimated profit, loss, and ROI performance.
Based on your investment of $1,000.00 in Calliditas Therapeutics AB (publ) and holding until April 17th, 2027, you could face a potential +$255.46 profit, reflecting a +25.5% ROI over the next 365 days. These projections help you better understand short-term market movements.
$Shares Bought
24.9999
@ $40.00/share
~Forecast Price
$50.22
1-year AI forecast
$Est. Portfolio Value
$1,255.46
+$255.46 profit
%ROI
+25.5%
return on investment
Calliditas Therapeutics AB (publ) yearly Price Forecast Chart
Explore the yearly forecast chart for CALT, which maps expected price movement, support levels, and resistance targets. The dropdown lets you view forecasts across multiple horizons, from short-term daily trends to 7-year projections, helping investors evaluate Calliditas Therapeutics AB (publ) over different timeframes.
No forecast data available
No prediction data found for this time period.
Forecasting data is not available for CALTForecasting details for CALT are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.Calliditas Therapeutics AB (publ) Stock Forecast 2026
The forecast for Calliditas Therapeutics AB (publ) (CALT) in 2026 suggests a price of $50.22, representing a 25.55% move from today’s price.
Average Target: $50.22
Market Outlook: bullish based on current trend indicators.
Key Drivers in 2026:- Earnings growth projections.
- Competitive performance in the Healthcare.
- Macroeconomic factors such as interest rates and inflation.
Calliditas Therapeutics AB (publ) Stock Forecast 2030
By 2030, Meyka AI projects CALT could trade near $80.89, showing a potential 102.23% compared to current levels.
Average Target: $80.89
Market Outlook: bullish.
What could influence the 2030 forecast:- Technological innovation and product cycles.
- Expansion into global markets.
- Long-term investor sentiment toward Calliditas Therapeutics AB (publ).
Calliditas Therapeutics AB (publ) 7-Year Stock Forecast (2032–2033)
Looking 7 years ahead, the long-term forecast for CALT points to a price around $83.17, which is a projected 107.91% move from today’s level.
Average Target: $83.17
Outlook: bullish, depending on macroeconomic conditions and sector growth.
Long-Term Drivers:- Global economic expansion or contraction.
- Regulatory and policy environment.
- Calliditas Therapeutics AB (publ)’s ability to maintain market leadership.